MeiraGTx Holdings (MGTX) Other Operating Expenses (2024 - 2026)
MeiraGTx Holdings' (MGTX) quarterly Other Operating Expenses came in at $30.8 million in Q4 2025, down 71.34% YoY from $107.5 million in Q4 2024, and down 5.29% on a QoQ basis from $32.5 million in Q3 2025.
Powered by 
Analysis
MeiraGTx Holdings (MGTX) Other Operating Expenses (2024 - 2026) Analysis & Trends
MeiraGTx Holdings (MGTX) has 2 years of Other Operating Expenses data on file, last reported at $30.8 million in Q4 2025.
- Quarterly Other Operating Expenses fell 71.34% year-over-year to $30.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $129.6 million (up 8.48% YoY) and the FY2025 annual result came in at $129.6 million, up 8.48% from the prior year.
- Other Operating Expenses eased to $30.8 million in Q4 2025, from $32.5 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $107.5 million in Q4 2024 to a low of $12.0 million in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | MeiraGTx Holdings | 1.27 Bn | 1.13 Bn | 315.67 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.16 Mn |
| Dec 31, 2025 | 476,000.00 |
| Sep 30, 2025 | 313,000.00 |
| Jun 30, 2025 | 2.68 Mn |
| Mar 31, 2025 | 1.38 Mn |
| Dec 31, 2024 | 11.81 Mn |
| Sep 30, 2024 | 11.99 Mn |